Company Overview - GT Biopharma, Inc. is a clinical stage immuno-oncology company focused on developing therapeutics based on its proprietary TriKE platform, which enhances the cancer-killing abilities of natural killer (NK) cells [2][4] - The company has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology [2] Upcoming Events - The company will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City [1] - An on-demand webcast of the company's presentation will be available starting at 7:00 a.m. ET on September 5, 2025 [2] Clinical Trials - The Phase 1 trial for GTBP-3650, aimed at treating relapsed or refractory CD33 expressing hematologic malignancies, is continuing to enroll as expected, with initial results from multiple dose cohorts anticipated later in 2025 [1] - The company is on track for the IND submission of GTB-5550 TriKE for the treatment of B7H3 positive solid tumors in Q4 2025 [1]